Format

Send to

Choose Destination
Gynecol Endocrinol. 2011 Oct;27(10):789-93. doi: 10.3109/09513590.2010.540600. Epub 2011 Jan 19.

Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study.

Author information

1
Egyptian International fertility & IVF Center, Miser International Hospital, Cairo, Egypt.

Abstract

BACKGROUND:

Women with polycystic ovary syndrome (PCOS) are at a high risk to develop Gestational Diabetes mellitus (GDM). We hypothesized that metformin due to its metabolic, endocrine, vascular, and anti-inflammatory effects may reduce the incidence of GDM in PCOS women.

PATIENT AND METHOD:

We carried out a prospective cohort study to determine the beneficial effects of metformin on PCOS patients during pregnancy. Three-hundred and sixty non-diabetic PCOS patients were included who were conceived on metformin by different treatment modalities. Two-hundred pregnant women continued on metformin at a dose of 1000-2000 mg daily throughout pregnancy (study group) and 160 women discontinued metformin use at the time of conception (control group).

RESULTS:

There is a statistically significant reduction in the incidence of GDM in favor of metformin group (OR: 0.17, 95% CI: 0.07-0.37). There is a statistically significant reduction in the incidence of pre-eclampsia in favor of metformin group (OR: 0.35, 95% CI: 0.13-0.94).

CONCLUSION:

Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women.

PMID:
21247239
DOI:
10.3109/09513590.2010.540600
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center